Terms: = Breast cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Clinical Outcome
20 results:
1. Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.
Yoshitake R; Mori H; Ha D; Wu X; Wang J; Wang X; Saeki K; Chang G; Shim HJ; Chan Y; Chen S
Clin Transl Med; 2024 Jan; 14(1):e1548. PubMed ID: 38282415
[TBL] [Abstract] [Full Text] [Related]
2. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N; Fasching PA; Wuerstlein R; Degenhardt T; Lüftner D; Kates RE; Schumacher J; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Schinköthe T; Schmidt M;
Ann Oncol; 2023 Aug; 34(8):660-669. PubMed ID: 37201751
[TBL] [Abstract] [Full Text] [Related]
3. High p16 expression and heterozygous RB1 loss are biomarkers for cdk4/6 inhibitor resistance in ER
Palafox M; Monserrat L; Bellet M; Villacampa G; Gonzalez-Perez A; Oliveira M; Brasó-Maristany F; Ibrahimi N; Kannan S; Mina L; Herrera-Abreu MT; Òdena A; Sánchez-Guixé M; Capelán M; Azaro A; Bruna A; Rodríguez O; Guzmán M; Grueso J; Viaplana C; Hernández J; Su F; Lin K; Clarke RB; Caldas C; Arribas J; Michiels S; García-Sanz A; Turner NC; Prat A; Nuciforo P; Dienstmann R; Verma CS; Lopez-Bigas N; Scaltriti M; Arnedos M; Saura C; Serra V
Nat Commun; 2022 Sep; 13(1):5258. PubMed ID: 36071033
[TBL] [Abstract] [Full Text] [Related]
4. Co-targeting cdk4/6 and AKT with endocrine therapy prevents progression in cdk4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of the Effectiveness and clinical outcome of Everolimus Followed by cdk4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic breast cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract] [Full Text] [Related]
6. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
[TBL] [Abstract] [Full Text] [Related]
7. Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR
Dandachi N; Posch F; Graf R; Suppan C; Klocker EV; Müller HD; Lindenmann J; Terbuch A; Heitzer E; Balic M
Mol Oncol; 2021 Sep; 15(9):2390-2400. PubMed ID: 33264486
[TBL] [Abstract] [Full Text] [Related]
8. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced breast cancer.
O'Leary B; Cutts RJ; Huang X; Hrebien S; Liu Y; André F; Loibl S; Loi S; Garcia-Murillas I; Cristofanilli M; Bartlett CH; Turner NC
J Natl Cancer Inst; 2021 Mar; 113(3):309-317. PubMed ID: 32940689
[TBL] [Abstract] [Full Text] [Related]
9. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (cdk4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group.
Fountzilas E; Koliou GA; Vozikis A; Rapti V; Nikolakopoulos A; Boutis A; Christopoulou A; Kontogiorgos I; Karageorgopoulou S; Lalla E; Tryfonopoulos D; Boukovinas I; Rapti C; Nikolaidi A; Karteri S; Moirogiorgou E; Binas I; Mauri D; Aravantinos G; Zagouri F; Saridaki Z; Psyrri A; Bafaloukos D; Koumarianou A; Res E; Linardou H; Mountzios G; Razis E; Fountzilas G; Koumakis G
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817060
[TBL] [Abstract] [Full Text] [Related]
10. Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Doucette K; Lai C; Pohlmann PR
Breast J; 2020 Oct; 26(10):2031-2033. PubMed ID: 32639043
[TBL] [Abstract] [Full Text] [Related]
11. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
[TBL] [Abstract] [Full Text] [Related]
12. cdk4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism.
Zhang Z; Li J; Ou Y; Yang G; Deng K; Wang Q; Wang Z; Wang W; Zhang Q; Wang H; Sun W; Sun P; Yang S
Signal Transduct Target Ther; 2020 Mar; 5(1):25. PubMed ID: 32296027
[TBL] [Abstract] [Full Text] [Related]
13. The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy.
Fiorillo M; Sanchez-Alvarez R; Sotgia F; Lisanti MP
Aging (Albany NY); 2018 Dec; 10(12):4000-4023. PubMed ID: 30573703
[TBL] [Abstract] [Full Text] [Related]
14. Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer.
De Luca A; Maiello MR; D'Alessio A; Frezzetti D; Gallo M; Carotenuto M; Normanno N
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):891-900. PubMed ID: 30130984
[TBL] [Abstract] [Full Text] [Related]
15. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
O'Leary B; Hrebien S; Morden JP; Beaney M; Fribbens C; Huang X; Liu Y; Bartlett CH; Koehler M; Cristofanilli M; Garcia-Murillas I; Bliss JM; Turner NC
Nat Commun; 2018 Mar; 9(1):896. PubMed ID: 29497091
[TBL] [Abstract] [Full Text] [Related]
16. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
Oh YJ; Park SY; Seo YH
Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
[TBL] [Abstract] [Full Text] [Related]
17. Recent advances of highly selective cdk4/6 inhibitors in breast cancer.
Xu H; Yu S; Liu Q; Yuan X; Mani S; Pestell RG; Wu K
J Hematol Oncol; 2017 Apr; 10(1):97. PubMed ID: 28438180
[TBL] [Abstract] [Full Text] [Related]
18. Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression.
Boulay PL; Mitchell L; Turpin J; Huot-Marchand JÉ; Lavoie C; Sanguin-Gendreau V; Jones L; Mitra S; Livingstone JM; Campbell S; Hallett M; Mills GB; Park M; Chodosh L; Strathdee D; Norman JC; Muller WJ
Cancer Res; 2016 May; 76(9):2662-74. PubMed ID: 26933086
[TBL] [Abstract] [Full Text] [Related]
19. breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
Laurent C; Delas A; Gaulard P; Haioun C; Moreau A; Xerri L; Traverse-Glehen A; Rousset T; Quintin-Roue I; Petrella T; Emile JF; Amara N; Rochaix P; Chenard-Neu MP; Tasei AM; Menet E; Chomarat H; Costes V; Andrac-Meyer L; Michiels JF; Chassagne-Clement C; de Leval L; Brousset P; Delsol G; Lamant L
Ann Oncol; 2016 Feb; 27(2):306-14. PubMed ID: 26598546
[TBL] [Abstract] [Full Text] [Related]
20. Posttranslational modifications of p27kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo.
Zhang W; Bergamaschi D; Jin B; Lu X
Blood; 2005 May; 105(9):3691-8. PubMed ID: 15665120
[TBL] [Abstract] [Full Text] [Related]
